Clincosm LogoSign in Get a demo

Recurrent Uterine Corpus Carcinoma

Showing 1 - 20 of 20
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 16, 2022

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +4 more
  • Akt Inhibitor MK2206
  • Laboratory Biomarker Analysis
  • Boston, Massachusetts
  • +6 more
Jan 13, 2022

Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7 Trial in

Completed
Has Results
  • Recurrent Uterine Corpus Carcinoma
  • +5 more
  • Birmingham, Alabama
  • +649 more
Sep 28, 2021

Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in Canada, United

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +7 more
  • Sunitinib Malate
  • Beverly Hills, California
  • +28 more
Feb 14, 2020

Cervical Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma Trial in Bronx (Palliative Therapy, Palliative Therapy +

Completed
  • Cervical Carcinoma
  • +9 more
  • Palliative Therapy
  • Palliative Therapy + idiographic
  • Bronx, New York
    Albert Einstein College of Medicine
Sep 13, 2019

Endometrial Adenocarcinoma, ERBB2 Gene Amplification, Recurrent Uterine Corpus Carcinoma Trial in Philadelphia (Laboratory

Completed
  • Endometrial Adenocarcinoma
  • +4 more
  • Laboratory Biomarker Analysis
  • Trastuzumab
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
Jul 30, 2019

Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer Trial in United States (Laboratory

Completed
Has Results
  • Endometrial Carcinoma
  • +7 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Burbank, California
  • +107 more
Jul 19, 2019

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +3 more
  • Los Angeles, California
  • +71 more
Jul 19, 2019

Recurrent Uterine Corpus Carcinoma Trial in Philadelphia (Gefitinib, Laboratory Biomarker Analysis)

Completed
  • Recurrent Uterine Corpus Carcinoma
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
Jul 22, 2019

Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7 Trial

Unknown status
Has Results
  • Recurrent Uterine Corpus Carcinoma
  • +2 more
  • (no location specified)
Mar 8, 2019

Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma Trial in Canada,

Completed
Has Results
  • Adult Hepatocellular Carcinoma
  • +44 more
  • Scottsdale, Arizona
  • +60 more
Jan 24, 2019

Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +8 more
  • Brivanib Alaninate
  • Laboratory Biomarker Analysis
  • Aurora, Colorado
  • +34 more
Nov 2, 2017

Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +8 more
  • Burbank, California
  • +58 more
Sep 8, 2017

Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma Trial in United

Completed
  • Endometrial Adenosquamous Carcinoma
  • +10 more
  • Hartford, Connecticut
  • +8 more
Aug 23, 2017

Prognostic Biomarkers in Patients With Endometrial Cancer

Completed
  • Endometrial Adenocarcinoma
  • +5 more
  • Laboratory Biomarker Analysis
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
Aug 22, 2017

Collecting Tumor Samples From Patients With Gynecological Tumors

Completed
  • Borderline Ovarian Clear Cell Tumor
  • +85 more
  • Laboratory Biomarker Analysis
  • Fayetteville, Arkansas
  • +186 more
Oct 26, 2016

Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma Trial in Buffalo (biological, other, drug)

Completed
  • Anaplastic Astrocytoma
  • +64 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 3, 2016

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +7 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
Mar 17, 2016

Tumor Tissue Samples From Stage III, Stage IV, or Recurrent

Not yet recruiting
  • Recurrent Uterine Corpus Carcinoma
  • +2 more
  • Laboratory Biomarker Analysis
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
Jun 3, 2015

Biomarkers in Samples From Patients With Endometrial Cancer

Not yet recruiting
  • Lynch Syndrome
  • +5 more
  • Laboratory Biomarker Analysis
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
May 27, 2015